One of the hottest topics in the research world for chronic myeloid leukemia is, "Can my patients ever stop therapy?" And the answer is there may be a subgroup of patients who can. French investigators in the STIM trials have shown that up to 40% of patients who are in a deep molecular response could remain off medications, not really cured, but low enough levels that the immune system can hold them under control. Who are the patients who might be eligible? It is those patients who have suppressed their PCR on the international scale by more than 4.5 logs and have maintained that for more than 2 years. These patients then need to be followed on a monthly basis for the first critical year because 60% of them will unfortunately relapse very quickly within the first 6 months. If we follow them very closely and restart the medication, we can recapture almost every patient. Therefore, there may be a subgroup of patients who can stop treatment. More studies are ongoing including studies here in the United States.For more information on managing your patients with CML, and to participate in an interactive case study in which you’ll be able to make clinical decisions for a patient with CP-CML, please view the activity available here.